These results indicate that dasatinib enhances the anti-tumor effect in the BTZ-resistant model through inhibition of Lyn, suggesting that dasatinib treatment could have potential therapeutic value in BTZ-resistant MCL. This evidence concerns the gene LYN and mantle cell lymphoma.